Articles
Lung cancer is the leading cause of death from cancer worldwide, estimated to be responsible for nearly 1 in 5 cancer deaths in 2012 (1.59 million deaths, 19.4% of total cancer deaths). In the United States, lung cancer is the second most frequently diagnosed cancer, with an estimated 224,390 new cases in 2016, representing the leading cause of cancer death in Americans. Read More ›
Jennifer Brown, MD, PhD, expanded upon the results of her and her colleagues’ study of the hepatotoxic effects of idelalisib, particularly as frontline treatment of younger patients with chronic lymphocytic leukemia, which was presented at the 57th American Society of Hematology Annual Meeting & Exposition. Read More ›
William A. Zellmer, BPharm, MPH, discusses how the 4th edition of the American Society of Health-System Pharmacists (ASHP) Foundation’s Pharmacy Forecast serves to improve the effectiveness of leaders in hospital and health-system pharmacy practice. Read More ›
The American Society of Health-System Pharmacists (ASHP) Foundation's Pharmacy Forecast, now in its fourth edition, serves to improve the effectiveness of leaders in hospital and health-system pharmacy practice. Read More ›
Here is a review of study results of various medications being reported from different conferences. Read More ›
Here is an overview of oncology medications that were recently approved by the U.S. Food and Drug Administration. Read More ›
Guidelines for enoxaparin dose reduction when treating chemotherapy-induced thrombocytopenia (CIT) have been validated by a quality assessment study conducted at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. Read More ›
Orlando, FL–New agents with novel targets have revolutionized management of chronic lymphocytic leukemia (CLL). However, all drugs have risks and benefits. At the 57th American Society of Hematology (ASH) Annual Meeting & Exposition, 3 separate presentations highlighted toxicity concerns related to idelalisib, ibrutinib, and venetoclax: hepatotoxicity with idelalisib, drug–drug interactions with ibrutinib, and the need for careful dosing at initiation of venetoclax. Read More ›
In the February issue of The Oncology Pharmacist, we feature a recent study that was presented at the 2015 Palliative Care in Oncology Symposium on aprepitant (Emend), a centrally acting neurokinin-1 antagonist indicated for patients with chemotherapy-induced nausea and vomiting. Read More ›
An open-label, randomized, phase 2 study evaluated the all-oral triplet combination of ixazomib (an orally administered proteasome inhibitor) plus cyclophosphamide (at 2 different doses) and low-dose dexamethasone (ICd) as a 12-month induction therapy in previously untreated, transplant-ineligible patients with multiple myeloma (MM). Read More ›